Cancel
Miles Congreve
Chief Scientific Officer
@
Isomorphic Labs
x37qw.090wk66t@8jz150f01q9w9j.95t
Sign up to see email
Known information
- Helped design 20 clinically evaluated drugs
- Co-inventor of Kisqali (Ribociclib), a marketed treatment for breast cancers
- Pioneered Structure-Based Drug Design for G Protein-Coupled Receptors (GPCRs) at Sosei Heptares
- Established Fragment-Based Drug Design as a new approach to small molecule lead generation at Astex Pharmaceuticals
- Former team leader at GlaxoSmithKline in medicinal chemistry and chemical technologies
- Co-author of over 200 publications and patents
- Fellow of the Royal Society of Chemistry
- Co-recipient of the RSC Malcolm Campbell Memorial Prize in 2015 for contributions to GPCR drug discovery
- Holds a degree in biological chemistry from Leicester University
- Earned a PhD in synthetic chemistry from Cambridge University
About Isomorphic Labs
Isomorphic Labs, founded in 2021, is an Alphabet subsidiary leveraging AI and computational methods, including their development of AlphaFold 3, to revolutionize drug discovery.
Report inaccurate information
